We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ceres Nanoscience Opens $9M Series A Round

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Ceres Nanosciences, Inc. today announced the completion of a $3M Million Series A financing as part of a larger, $9M Series A round. GreyBird Ventures, an early stage venture fund, with offices in Boston, is leading the round. GreyBird is committing up to $5.5M over the next year, and is supporting Ceres in completing the round with additional investment from strategic industry partners.

Ceres, a biotechnology company located in northern Virginia, has developed and commercialized a novel nanoparticle technology, the “Nanotrap®”, which provides powerful biomarker capture and biofluid sample processing capabilities for a wide array of diagnostic applications and sample handling needs.

The Nanotrap technology was invented at George Mason University and developed under funding from the National Institutes of Health (NIH) for biomarker discovery applications. With support from the NIH, the Defense Advanced Research Projects Agency (DARPA), the Bill and Melinda Gates Foundation, and the Commonwealth of Virginia, Ceres is focused on incorporating this technology into a range of innovative diagnostic products. Ceres’ lead product is a first-of-its-kind urine-based Lyme Antigen test that will provide the most sensitive detection of Lyme disease.

“This marks a very big milestone for Ceres, and the timing could not be better, as there is a growing demand from patients and physicians, alike, for better ways to conduct non-invasive and highly accurate testing,” said Ceres CEO Ross Dunlap. “Our Nanotrap® technology platform will enable a convenient way of detecting Lyme disease, routinely and effectively, using a patient’s urine sample and a simple point-of-care test device. This will set the stage for delivering many new high-accuracy and patient-friendly tests based on this platform.”

Emanuel “Chip” Petricoin, PhD, one of the co-inventors of the Nanotrap® and a co-founder of Ceres, explained, “One of the biggest limitations in clinical diagnostics today is that most of the biomarkers that could transform healthcare exist in concentrations too low to be detected by current testing methods. Ceres stands poised to change the medical landscape by providing a transformative technology that can power clinical diagnostics to a level not seen before.”

Tom Miller, a co-founder of GreyBird Ventures, who has joined Ceres’ board, said, “Ceres has solved a
fundamental problem in precision medicine, concentrating the most interesting biomarkers of early stage disease that have a low natural abundance. The Lyme test is just the first example. We are very pleased to be involved with Ceres not only because of its financial promise but primarily due to our expectation of the very large number of patients whose health will benefit.”

This article has been republished from materials provided by Ceres Nano. Note: material may have been edited for length and content. For further information, please contact the cited source.